CSF3 and breast carcinoma: Breast cancer patients who did not receive prophylactic G-CSF (median age = 52 years) were significantly younger than those who received G-CSF ≤ 30 days before the start of chemotherapy (median age = 55 years) or those who received G-CSF after chemotherapy initiation (median age = 52 years) (Supplementary Table S1).